FibroGen
Ms. Chung, Senior Vice President, China Operations, and Managing Director of our subsidiary company, FibroGen China. She joined the company in 2007 and brings more than 25 years of experience in growing businesses from start-up through various phases of corporate development. Ms. Chung serves in the role of Project Leader of our U.S.-based China development efforts and has overall responsibility for our China local operations. Under Ms. Chung’s leadership, our China strategy has advanced from conceptualization to pre-launch stage. Prior to joining FibroGen, Ms. Chung was Vice President, Business Development, at eMed Technologies and a management consultant with Monitor Group, the predecessor company of Monitor Deloitte. Ms. Chung received her B.A., magna cum laude, from Harvard University and is a native of Hong Kong.
This person is not in any offices
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.